Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Sutro Biopharma Inc (STRO)

Sutro Biopharma Inc (STRO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 820,335
  • Shares Outstanding, K 38,604
  • Annual Sales, $ 42,740 K
  • Annual Income, $ -55,740 K
  • 60-Month Beta 0.79
  • Price/Sales 13.25
  • Price/Cash Flow N/A
  • Price/Book 3.64
Trade STRO with:

Options Overview

Details
  • Implied Volatility 101.56%
  • Historical Volatility 61.54%
  • IV Percentile 40%
  • IV Rank 20.13%
  • IV High 218.88% on 12/28/20
  • IV Low 72.00% on 01/08/21
  • Put/Call Vol Ratio 0.00
  • Today's Volume 93
  • Volume Avg (30-Day) 135
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 425
  • Open Int (30-Day) 1,239

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/20
See More
  • Average Estimate -0.54
  • Number of Estimates 6
  • High Estimate -0.33
  • Low Estimate -0.77
  • Prior Year -0.64
  • Growth Rate Est. (year over year) +15.63%

Price Performance

See More
Period Period Low Period High Performance
1-Month
21.01 +1.14%
on 02/26/21
28.30 -24.91%
on 02/08/21
-3.16 (-12.95%)
since 02/03/21
3-Month
19.61 +8.36%
on 12/08/20
28.30 -24.91%
on 02/08/21
+4.25 (+25.00%)
since 12/03/20
52-Week
6.00 +254.17%
on 03/19/20
28.30 -24.91%
on 02/08/21
+11.57 (+119.52%)
since 03/03/20

Most Recent Stories

More News
Sutro Biopharma to Participate in the Cowen 41st Annual Healthcare Conference

, /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design...

STRO : 21.25 (-5.05%)
Sutro Biopharma Announces First Patient Dosed in the Dose-Expansion Study of STRO-002 in Patients with Ovarian Cancer

, /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design...

STRO : 21.25 (-5.05%)
Sutro Biopharma to Present at the 39th Annual J.P. Morgan Virtual Healthcare Conference

, /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design...

JPM : 152.91 (+1.93%)
STRO : 21.25 (-5.05%)
Sutro Biopharma Announces Closing of Upsized $144.9 Million Public Offering, including Full Exercise of the Underwriters' Option to Purchase Additional Shares

, /PRNewswire/ -- Sutro Biopharma, Inc. (Nasdaq: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design...

STRO : 21.25 (-5.05%)
Sutro Biopharma Announces Pricing of $126.0 Million Public Offering

, /PRNewswire/ -- Sutro Biopharma, Inc. (Nasdaq: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design...

STRO : 21.25 (-5.05%)
Sutro Biopharma Announces Proposed Public Offering of 5 Million Shares of Common Stock

, /PRNewswire/ -- Sutro Biopharma, Inc. (Nasdaq: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design...

STRO : 21.25 (-5.05%)
Sutro Biopharma Presents Data from Ongoing Phase 1 Dose-Escalation Study for STRO-001 for the Treatment of B-cell Non-Hodgkin Lymphoma at the 62nd American Society of Hematology Annual Meeting

, /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design...

STRO : 21.25 (-5.05%)
Thinking about buying stock in Sutro Biopharma, BioCryst Pharmaceuticals, Inovio Pharmaceuticals, Cocrystal Pharma, or Clean Energy Fuels?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for STRO, BCRX, INO, COCP, and CLNE.

BCRX : 11.87 (+1.11%)
CLNE : 12.26 (-7.33%)
COCP : 1.5300 (-4.38%)
INO : 9.56 (-4.59%)
STRO : 21.25 (-5.05%)
Sutro Biopharma Announces Encouraging Interim Data on STRO-002 Phase 1 Dose-Escalation Study for Patients with Ovarian Cancer

, /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design...

STRO : 21.25 (-5.05%)
Sutro Biopharma Announces Appointment of Jon M. Wigginton, M.D., to Board of Directors

, /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design...

STRO : 21.25 (-5.05%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Sutro Biopharma Inc. develops and manufactures pharmaceutical products. The Company provides antibody drug conjugate and multi-specific antibody-based therapeutics for cancer therapy. Its product pipeline consists of STRO-001 and STRO-002 which are in clinical stage. Sutro Biopharma Inc. is based in...

See More

Key Turning Points

3rd Resistance Point 24.33
2nd Resistance Point 23.67
1st Resistance Point 22.46
Last Price 21.25
1st Support Level 20.59
2nd Support Level 19.93
3rd Support Level 18.72

See More

52-Week High 28.30
Last Price 21.25
Fibonacci 61.8% 19.78
Fibonacci 50% 17.15
Fibonacci 38.2% 14.52
52-Week Low 6.00

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar